SYMPHONY PREDICTIONS

SYMPHONY PREDICTIONS

Trials with limitations 

The below list represents drug candidates in Phase 2 clinical trails that our Symphony™ platform provides rationale for efficacy, however,  our scientists and researchers have questions or concerns as noted below.

See our list of candidates we predict will achieve efficacy in Phase 2 trials. 

DISEASE

DRUG

MECHANISM OF ACTION

NOVEL MECHANISM OF ACTION IN DISEASE

CLINICAL TRIAL

END DATE

CLINICAL TRIAL LINK

PREDICTION PUBLISHED DATE

REASON FOR CONCERN

Systemic Sclerosis (SSc)

SHP-627

TGFB1 & PDGF Inhibitor

No

November 2022

clinicaltrials.gov

August 31, 2022

Too few patients in the clinical trial (30); also concerns about the potency and selectivity of the reported mechanism of action

Ankylosing Spondylitis

Jaktinib 

JAK inhibitor

No

December 2022

clinicaltrials.gov

August 31, 2022

Tolerability given Jaktinib's broad JAK inhibition

Atopic Dermatitis

Jaktinib

JAK inhibitor-

No

December 2022

clinicaltrials.gov

August 31, 2022

Tolerability given Jaktinib's broad JAK inhibition

Lupus Nephritis

Pegcetacoplan

C3 inhibitor

Yes

December 2022

clinicaltrials.gov

August 31, 2022

Too few patients in the clinical trial (21)

SYMPHONY™

Aria’s drug discovery engine.

Drug discovery is complex. Our technology decodes complex biology in an unprecedented manner, combining the widest biomedical data landscapes available with proprietary, purpose-built artificial intelligence. Symphony™ is the only AI drug discovery platform that integrates and simultaneously analyzes unrelated heterogenous data in one process. We see the whole picture, increasing our chance of fully understanding the biology and detecting a signal others can’t see.